Thyroid dysfunction in thalassaemic patients: Ferritin as a prognostic marker and combined iron chelators as an ideal therapy

European Journal of Endocrinology

Volumn 169, Issue 6, 2013, Pages 785-793

  Chirico, Valeria ^a   Antonio, Lacquaniti ^a,b   Vincenzo, Salpietro ^a   Luca, Nicoletta ^a   Valeria, Ferraù ^a   Basilia, Piraino ^a   Luciana, Rigoli ^a   Carmelo, Salpietro ^a   Teresa, Arrigo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; FERRITIN; IRON CHELATING AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; BETA THALASSEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; THYROID DISEASE; TREATMENT RESPONSE; AGED; BETA-THALASSEMIA; BLOOD; CHELATION THERAPY; COMPARATIVE STUDY; COMPLICATION; EPIDEMIOLOGY; ITALY; KAPLAN MEIER METHOD; MIDDLE AGED; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK; RISK ASSESSMENT; RISK FACTOR; THYROID DISEASES; TREATMENT OUTCOME;

ADULT; AGED; BETA-THALASSEMIA; BIOLOGICAL MARKERS; CHELATION THERAPY; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; FERRITINS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; IRON CHELATING AGENTS; IRON OVERLOAD; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; THYROID DISEASES; TREATMENT OUTCOME;

EID: 84888234480     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0627     Document Type: Article

References (28)

1. Abdulzahra MS, Al-Hakeim HK & Ridha MM. Study of the effect of iron overload on the function of endocrine glands in male thalassemia patients. Asian Journal of Transfusion Science 2011 5 127-131. (doi:10.4103/0973-6247.83236)
2. Musallam KM, Cappellini MD & Taher AT. Iron overload in b-thalassemia intermedia: an emerging concern. Current Opinion in Hematology 2013 20 187-192. (doi:10.1097/MOH.0b013 e32835f5a5c)
3. Malik SA, Syed S & Ahmed N. Frequency of hypothyroidism in patients of β-thalassemia. Journal of Pakistan Medical Association 2010 60 17-29.
4. Zervas A, Katopodi A, Protonotariou A, Livadas S, Karagiorga M, Politis C & Tolis G. Assessment of thyroid function in two hundred patients with β-thalassemia major. Thyroid 2002 12 151-154. (doi:10.1089/ 105072502753522383)
5. Aydinok Y, Darcan S, Polat A, Kavakli K, Nigli G, Coker M, Kantar M & Cetingul N. Endocrine complications in patients with b-thalassemia major. Journal of Tropical Pediatrics 2002 48 50-54. (doi:10.1093/tropej/48.1.50)
6. Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, Giardina PJ, Vichinsky E, Olivieri N et al. Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica 2008 93 817-825. (doi:10.3324/haematol.11755)
7. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004 89 1187-1193.
8. De Sanctis VD, Soliman A & Yassin M. Iron overload and glucose metabolism in subjects with β-thalassaemia major: an overview. Current Diabetes Reviews 2013 9 332-341. (doi:10.2174/1573399811309040005)
9. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P & Lucarelli G. Hepatic iron concentration and total body iron stores in thalassemia major. New England Journal of Medicine 2000 343 327-331. (doi:10.1056/NEJM200008033430503)
10. Kalinowski DS & Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacological Reviews 2005 57 547-583. (doi:10.1124/pr.57.4.2)
11. Ward A, Caro JJ, Green TC, Huybrechts K, Arana A, Wait S & Eleftheriou A. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clinical Pharmacology 2002 2 3. (doi:10.1186/1472-6904-2-3)
12. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR & Thalassemia Clinical Research Network. Complications of b-thalassemia major in North America. Blood 2004 104 34-39. (doi:10.1182/blood-2003-09-3167)
13. Taher AT, Sheikh-Taha M, Sharara A, Inati A, Koussa S, Ellis G, Dhillon AP & Hoffbrand AV. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two year study. Acta Haematologica 2005 114 146-149. (doi:10.1159/000087888)
14. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orallyadministered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006 91 873-880.
15. Farmaki K, Tzoumari I, Pappa C, Chouliaras G & Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. British Journal of Haematology 2010 148 466-475. (doi:10.1111/j.1365-2141.2009.07970.x)
16. Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, Fucharoen S, Cianciulli P, Grady RW, Prossomariti L et al. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells, Molecules & Diseases 2011 47 166-175. (doi:10.1016/j.bcmd.2011.07.002)
17. Malago R, D'Onofrio M, Ferdeghini M, Mantovani W, Colato C, Brazzarola P, Motton M & Mucelli RP. Thyroid volumetric quantification: comparative evaluation between conventional and volumetric ultrasonography. Journal of Ultrasound in Medicine 2008 27 1727-1733.
18. Haffner FM, Gonzales C, Miettinem H, Kennedy E & Stern MP. A prospective analysis of the HOMA model. Diabetes Care 1996 19 1138-1141. (doi:10.2337/diacare.19.10.1138)
19. Brewer CJ, Coates TD & Wood JC. Spleen R2 and R2 in ironoverloaded patients with sickle cell disease and thalassemia major. Journal of Magnetic Resonance Imaging 2009 29 357-364. (doi:10.1002/jmri.21666)
20. Mariotti S, Pigliaru F, Cocco MC, Spiga A, Vaquer S & Lai ME. β-thalassemia and thyroid failure: is there a role for thyroid autoimmunity? Pediatric Endocrinology Reviews 2011 8 307-309.
21. Pitrolo L, Malizia G, Lo Pinto C, Malizia V & Capra M. Ultrasound thyroid evaluation in thalassemic patients: correlation between the aspects of thyroidal stroma and function. Pediatric Endocrinology Reviews 2004 2 313-315.
22. Filosa A, Di Maio S, Aloj G & Acampora C. Longitudinal study on thyroid function in patients with thalassemia major. Journal of Pediatric Endocrinology & Metabolism 2006 19 1397-1404.
23. Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H & Taher AT. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica 2011 96 1605-1612. (doi:10.3324/haematol. 2011.047852)
24. Taher A, Musallam KM, El Rassi F, Duca L, Inati A, Koussa S & Cappellini MD. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. British Journal of Haematology 2009 146 569-572. (doi:10.1111/j.1365-2141.2009.07810.x)
25. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T et al. Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. American Journal of Hematology 2013 88 503-506. (doi:10.1002/ajh.23445)
26. Gardenghi S, Grady RW & Rivella S. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia. Hematology - Oncology Clinics of North America 2010 24 1089-1107. (doi:10.1016/j.hoc.2010.08.003)
27. Suvarna J, Ingle H & Deshmukh CT. Insulin resistance and β cell function in chronically transfused patients of thalassemia major. Indian Pediatrics 2006 43 393-400.
28. Soliman AT, Yasin M, El-Awwa A & De Sanctis V. Detection of glycemic abnormalities in adolescents with β thalassemia using continuous glucose monitoring and oral glucose tolerance in adolescents and young adults with β-thalassemia major: Pilot study. Indian Journal of Endocrinology and Metabolism 2013 17 490-495. (doi:10.4103/2230-8210.111647)